GlassScriptPhysician profile
Michael Pescatore Jacobson
NPI 1700406477
$6,241.52
in general payments reported to CMS, 2019-2025
22 companies · $247 in 2025
The $247 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $621 · 2022: $1,303 · 2023: $2,716 · 2024: $1,354 · 2025: $247.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,160 · Travel and Lodging: $140 · Education: $16.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,160.47 |
| Travel and Lodging | $140.00 |
| Education | $16.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $778.46 | 2022-2024 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $715.44 | 2022-2024 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $694.94 | 2021-2024 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Corium, LLC | $544.02 | 2022-2025 | Azstarys |
| Abbvie INC. | $534.29 | 2021-2025 | |
| Alkermes, INC. | $465.23 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Janssen Pharmaceuticals, INC | $425.03 | 2021-2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $378.94 | 2022-2024 | Austedo, Austedo Xr, Uzedy |
| Neurocrine Biosciences, INC. | $357.47 | 2021-2024 | Ingrezza |
| Axsome Therapeutics, INC. | $305.65 | 2022-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $215.56 | 2022-2024 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $175.00 | 2024 | |
| Vanda Pharmaceuticals INC. | $162.93 | 2022-2024 | Hetlioz, Fanapt |
| Lundbeck LLC | $131.52 | 2021-2023 | Rexulti |
| Idorsia Pharmaceuticals US INC | $65.90 | 2023 | Quviviq |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $65.72 | 2021-2024 | Trintellix |
| Tris Pharma INC | $56.75 | 2023 | Dyanavel Xr |
| Sunovion Pharmaceuticals INC. | $43.21 | 2021 | |
| Noven Therapeutics, LLC | $41.05 | 2021-2023 | Secuado |
| Vertical Pharmaceuticals, LLC | $30.11 | 2023-2024 | Relexxii |
| Indivior INC. | $28.47 | 2022-2023 | Perseris |
| Braeburn INC. | $25.83 | 2024 | Brixadi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Jacobson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.